Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
The study tested single-dose treatment at two CAR T-cell dose levels: 33 million and 100 million cells.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyverna Therapeutics (KYTX) announced updated Phase 1 data for miv-cel in progressive multiple sclerosis, showing stable to improved disability scores.
Stanford University's open-label, single-center study treated six patients; five had available efficacy data. All five had stable to improved Expanded Disability Status Scale scores at last follow-up, and 4/5 showed sustained clinical benefit through one year. Four patients with more than one year of follow-up sustained improvement without further chronic immunotherapies. The first treated patient maintained clinical benefit beyond two years.
No high-grade cytokine release syndrome or reported cases of ICANS or IEC-HS occurred. These preliminary findings require confirmation in larger controlled trials. Miv-cel received RMAT designation for non-active secondary progressive multiple sclerosis; Kyverna expects a development-strategy update by early 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointRMAT designation granted for miv-cel in non-active secondary progressive multiple sclerosis.
- Minor pointAll five evaluable patients had stable to improved disability scores at last follow-up.
- Minor point4/5 evaluable patients showed sustained clinical benefit through one year.
- Minor pointFour patients sustained improvement beyond one year without further chronic immunotherapies.
- Minor pointFirst treated patient maintained clinical benefit beyond two years.
5 minor points
- Minor pointSafety findings included no high-grade cytokine release syndrome and no reported immune effector cell-associated neurotoxicity or hemophagocytic lymphohistiocytosis-like syndromes.
- Minor pointCAR T cells expanded in blood and penetrated cerebrospinal fluid, with peak levels at approximately day 14.
- Minor pointAll participants achieved complete peripheral CD19-positive B-cell depletion, with repopulation beginning at month 3.
- Minor pointOne-year cerebrospinal fluid biomarkers continued to support a favorable immunological impact.
- Minor point. Forward-looking: it has not happened yet and may not happen.Development-strategy update is expected by early 2027, with Kyverna planning FDA discussions.
Negative
- Minor pointPreliminary evidence comes from an open-label, single-center study: six treated patients and five with available efficacy data.
- Minor pointClinical findings require confirmation in larger controlled trials.
Key Figures
- Patients treated
- 6 patients
- Phase 1 investigator-initiated trial
- Patients with efficacy data
- 5 patients
- Updated Phase 1 data
- Stable-to-improved disability scores
- 5 of 5 patients
- As of last follow-up
- Sustained clinical benefit
- 4 of 5 patients
- Through one year
- Benefit without chronic immunotherapies
- 4 patients
- More than one year of follow-up
- Longest reported benefit
- Beyond two years
- First patient treated
- Development strategy update
- By early 2027
- Progressive multiple sclerosis
Previous Clinical trial Reports
-
Earlier Stanford Phase 1 progressive MS findings reported disability stabilization and CNS penetration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
rmat designation regulatory
expanded disability status scale medical
icans medical
cerebrospinal fluid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies
Durable results extending beyond two years in the first patient treated
Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS
RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027
EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with progressive multiple sclerosis (PMS). The data will be shared today in an oral presentation at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting.
“There remains a substantial unmet need for therapies that can meaningfully alter the course of progressive multiple sclerosis,” said Jeffrey Dunn, MD, Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology at Stanford University. “In this early-phase study, miv-cel demonstrated encouraging tolerability, with evidence of CAR T-cell penetration into the central nervous system and biologic findings consistent with an immune reset. Importantly, we also observed sustained improvements in measures of neurologic disability and patient-reported function among evaluable participants. While these preliminary findings require confirmation in larger controlled trials, they provide an important proof of concept that miv-cel may offer a potential novel approach to treating progressive multiple sclerosis.”
Stanford Oral Presentation
Title: Safety and Preliminary Efficacy of CD-19 Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: A Phase 1 Study
Presenter: Jeff Dunn, M.D., Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology, Stanford University
Date & Time: Friday, October 23, 2026, 11:05 – 11:15 AM ET
Stanford University is conducting an open-label, Phase 1, single-center study of miv-cel in patients with non-relapsing progressive multiple sclerosis, either secondary progressive MS (SPMS) or primary progressive MS (PPMS). Six patients were treated with either 33M (n=3) or 100M (n=3) CAR T-cell dose levels using a bendamustine lymphodepleting (LD) regimen.
The oral presentation features updated data from six patients with available efficacy data from five patients, with follow-up of more than two years in the longest-treated patient. Key highlights include:
Efficacy:
- All five patients with available data demonstrated stable to improved expanded disability status scale scores (EDSS) as of last follow-up, with the majority (4/5) showing sustained clinical benefit through one year.
- Four patients with more than one-year of follow-up sustained improvement without further need for chronic immunotherapies. The first patient treated with miv-cel achieved sustained clinical benefit beyond two years.
Biological activity:
- Robust CAR T-cell expansion detected in peripheral blood and penetration in cerebrospinal fluid (CSF), with peak levels at approximately day 14.
- Complete depletion of CD19-positive peripheral B cells was achieved in all participants, followed by repopulation beginning at month 3, consistent with the emergence of naïve B cells, supporting evidence of immune reset.
- Additional biomarker data, including CSF oligoclonal bands and kappa free light chain, continue to support favorable immunological impact at one year.
Safety:
- Consistent, well-tolerated safety profile with no high-grade CRS and no reported cases of ICANS or IEC-HS.
“We are encouraged by the long-term durability and safety results with miv-cel in progressive multiple sclerosis, which add to the strong body of evidence supporting miv-cel’s transformative potential across neurologic autoimmune diseases,” said Naji Gehchan, Chief Medical and Development Officer of Kyverna Therapeutics. “The consistent, durable clinical benefit and well-tolerated safety profile observed across our indications are underpinned by miv-cel’s unique construct, specifically developed by Kyverna in autoimmune disease to enable immune reset by deeply and broadly depleting B-cells with a single dose. With our RMAT designation, we look forward to working with the FDA on our development plan in progressive multiple sclerosis and providing an update by early 2027.”
About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.
About Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disease causing neurodegeneration, in which patients can experience a range of symptoms including blurred vision, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, and, in severe cases, the inability to walk or stand, B cells play a significant role in MS by producing autoantibodies that attack the protective sheath around the nerves, activating T cells, and increasing inflammation. Current disease-modifying treatments for MS aim to reduce the frequence of disease relapse and delay a progression of disability, but the disease remains a chronic condition that will progressively worsen for most patients.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).
Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: miv-cel’s potential to meaningfully alter the course of, or offer a novel approach to treating, progressive multiple sclerosis; miv-cel’s transformative potential across neurologic autoimmune diseases; Kyverna’s development plans in progressive multiple sclerosis and expected timing for providing an update on its development strategy for multiple sclerosis; the potential for miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose or to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; Kyverna’s pipeline opportunities; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kyverna's miv-cel Phase 1 study show in progressive multiple sclerosis?
All five patients with available efficacy data had stable to improved Expanded Disability Status Scale scores at last follow-up. Four of five showed sustained clinical benefit through one year, and the first treated patient maintained clinical benefit beyond two years. The preliminary findings require confirmation in larger controlled trials.
What is the next development milestone for Kyverna's miv-cel in progressive multiple sclerosis?
Kyverna expects to provide a development-strategy update by early 2027. Miv-cel has received RMAT designation for non-active secondary progressive multiple sclerosis, and the company plans to work with the FDA on its development plan.
What doses and pretreatment were used in Kyverna's miv-cel progressive multiple sclerosis study?
Three patients received 33 million CAR T cells and three received 100 million CAR T cells, using a bendamustine lymphodepleting regimen to reduce immune cells before treatment. Stanford University conducted the study in patients with non-relapsing secondary progressive or primary progressive multiple sclerosis.
What biological activity did miv-cel show in Kyverna's progressive multiple sclerosis study?
CAR T cells expanded in peripheral blood and entered cerebrospinal fluid, with peak levels at approximately day 14. All participants achieved complete depletion of peripheral CD19-positive B cells, followed by repopulation beginning at month 3. Cerebrospinal fluid oligoclonal bands and kappa free light chain measurements continued to support a favorable immunological impact at one year.